First National Advisers LLC lowered its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 18.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,750 shares of the specialty pharmaceutical company’s stock after selling 4,753 shares during the quarter. First National Advisers LLC’s holdings in Jazz Pharmaceuticals were worth $2,555,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently modified their holdings of the company. Crossmark Global Holdings Inc. raised its holdings in shares of Jazz Pharmaceuticals by 23.6% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 5,083 shares of the specialty pharmaceutical company’s stock worth $567,000 after purchasing an additional 970 shares during the period. Los Angeles Capital Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $625,000. Victory Capital Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 23.3% in the 3rd quarter. Victory Capital Management Inc. now owns 253,299 shares of the specialty pharmaceutical company’s stock worth $28,220,000 after purchasing an additional 47,807 shares during the period. CIBC Asset Management Inc bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $209,000. Finally, Natixis Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 7.6% in the 3rd quarter. Natixis Advisors LLC now owns 22,834 shares of the specialty pharmaceutical company’s stock worth $2,544,000 after purchasing an additional 1,603 shares during the period. Institutional investors own 89.14% of the company’s stock.
Jazz Pharmaceuticals Stock Up 1.4 %
Shares of NASDAQ:JAZZ opened at $137.96 on Friday. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06. The firm has a fifty day moving average of $129.52 and a 200 day moving average of $120.81. The firm has a market capitalization of $8.38 billion, a PE ratio of 19.43, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.
Insider Buying and Selling
Analyst Ratings Changes
JAZZ has been the topic of a number of research reports. Barclays reaffirmed an “overweight” rating and issued a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Robert W. Baird boosted their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Morgan Stanley reissued an “overweight” rating and set a $183.00 target price (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Finally, Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Jazz Pharmaceuticals has an average rating of “Buy” and a consensus target price of $187.71.
Get Our Latest Research Report on Jazz Pharmaceuticals
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
See Also
- Five stocks we like better than Jazz Pharmaceuticals
- What Is WallStreetBets and What Stocks Are They Targeting?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What is the S&P/TSX Index?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.